Axiom International Investors LLC DE Has $37.14 Million Stake in Illumina, Inc. (NASDAQ:ILMN)

Axiom International Investors LLC DE boosted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 60.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 186,457 shares of the life sciences company’s stock after acquiring an additional 70,572 shares during the quarter. Axiom International Investors LLC DE owned 0.13% of Illumina worth $37,142,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Advisory Services Network LLC raised its stake in shares of Illumina by 13.0% in the 2nd quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock valued at $134,000 after acquiring an additional 89 shares in the last quarter. Penserra Capital Management LLC increased its position in Illumina by 13.0% in the 2nd quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock worth $153,000 after buying an additional 102 shares during the period. Dupont Capital Management Corp bought a new position in Illumina in the 3rd quarter worth approximately $153,000. Paradigm Asset Management Co. LLC increased its position in Illumina by 5.6% in the 2nd quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock worth $165,000 after buying an additional 50 shares during the period. Finally, NN Investment Partners Holdings N.V. increased its position in Illumina by 11.3% in the 2nd quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock worth $171,000 after buying an additional 100 shares during the period. Hedge funds and other institutional investors own 91.75% of the company’s stock.

Shares of Illumina, Inc. (NASDAQ ILMN) opened at $211.06 on Wednesday. The firm has a market capitalization of $31,163.70, a price-to-earnings ratio of 62.41, a P/E/G ratio of 3.53 and a beta of 0.79. The company has a current ratio of 4.22, a quick ratio of 3.73 and a debt-to-equity ratio of 0.41. Illumina, Inc. has a twelve month low of $119.37 and a twelve month high of $230.72.

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.99 by $0.12. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The business had revenue of $714.00 million during the quarter, compared to analyst estimates of $692.77 million. During the same period last year, the company earned $0.97 EPS. Illumina’s revenue for the quarter was up 17.6% compared to the same quarter last year. research analysts forecast that Illumina, Inc. will post 3.75 earnings per share for the current year.

In related news, SVP Oene Mark Van sold 9,729 shares of the business’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $211.33, for a total value of $2,056,029.57. Following the completion of the sale, the senior vice president now directly owns 24,908 shares of the company’s stock, valued at approximately $5,263,807.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Charles Dadswell sold 145 shares of Illumina stock in a transaction dated Tuesday, October 3rd. The shares were sold at an average price of $202.23, for a total value of $29,323.35. The disclosure for this sale can be found here. Over the last three months, insiders sold 164,005 shares of company stock valued at $34,243,898. Corporate insiders own 0.89% of the company’s stock.

Several analysts recently commented on the company. Barclays boosted their price target on Illumina from $150.00 to $185.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 25th. Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $229.00 price objective for the company in a research report on Friday, October 27th. Canaccord Genuity reiterated a “buy” rating and issued a $230.00 price objective (up previously from $215.00) on shares of Illumina in a research report on Thursday, October 12th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $226.00 price objective (up previously from $202.00) on shares of Illumina in a research report on Monday, October 9th. Finally, Janney Montgomery Scott upgraded Illumina from a “sell” rating to a “neutral” rating in a research report on Monday, October 23rd. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have issued a buy rating to the stock. Illumina presently has a consensus rating of “Buy” and an average target price of $201.98.

ILLEGAL ACTIVITY WARNING: This piece was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://stocknewstimes.com/2017/12/06/illumina-inc-ilmn-shares-bought-by-axiom-international-investors-llc-de.html.

Illumina Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply